Harris & Harris Group, Inc. announced today that it has invested in Cambrios Technologies Corporation, as part of a Series B funding round the company recently closed. Harris & Harris Group participated in this round of financing along with other new Series B investors, In-Q-Tel and Headland Ventures, and returning Series A investors, Alloy Ventures, ARCH Venture Partners, Avalon Ventures, Lux Capital, and Oxford Bioscience Partners.
Cambrios is a privately held company based in Mountain View, California that is developing commercial applications in the electronics industry based on a host of fabrication methodologies related to biologically-directed synthesis of inorganic materials. The approach is based on the directed-evolution technology invented by the company's founders, Dr. Angela Belcher of MIT and her longtime collaborator, Dr. Evelyn Hu of the University of California at Santa Barbara.
. Harris & Harris Group is a publicly traded venture capital company that now makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 20 initial private equity investments have been in tiny-technology enabled companies. The Company has 17,248,845 common shares outstanding.
Detailed information about Harris & Harris Group, Inc. and its holdings can be found on its website at http://www.TinyTechVC.com.
This news release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this new release. Please see the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc., undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.